TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer

BACKGROUND: In preclinical studies, the expression of vascular endothelial growth factor (VEGF) in hormone receptor-positive breast cancer is associated with estrogen-independent tumor growth and resistance to endocrine therapies. This study investigated whether the addition of bevacizumab, a monocl...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Breast Cancer Res
Main Authors: Vaklavas, Christos, Roberts, Brian S., Varley, Katherine E., Lin, Nancy U., Liu, Minetta C., Rugo, Hope S., Puhalla, Shannon, Nanda, Rita, Storniolo, Anna Maria, Carey, Lisa A., Saleh, Mansoor N., Li, Yufeng, Delossantos, Jennifer F., Grizzle, William E., LoBuglio, Albert F., Myers, Richard M., Forero-Torres, Andres
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2020
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7027068/
https://ncbi.nlm.nih.gov/pubmed/32070401
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13058-020-01258-x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados